MovDisordV3, PascalFrancis, Corpus, bibRecord, 001E66

Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements

Identifieur interne : 001E66 ( PascalFrancis/Corpus ); précédent : 001E65; suivant : 001E67

Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements

Auteurs : Valerie E. Kelly ; Amy J. Bastian

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0362495

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Chimiothérapie, Electromyographie.

English descriptors

KwdEn :
- Chemotherapy, Electromyography, Nervous system diseases, Parkinson disease.

Abstract

The execution of sequential arm movements is critical to activities of daily living such as eating and grooming. It is known that movement sequences are bradykinetic in people with Parkinson's disease (PD) and that antiparkinson medications improve the speed of movement sequences. However, it is unclear how muscle activity is modulated during sequential movements and what effect antiparkinson medications have on muscle modulation. We studied subjects with PD and age- and gender-matched control subjects making sequential reaching movements. Subjects with PD were tested before and after their morning dose of antiparkinson medications (levodopa and/or dopamine agonists). We examined the effect of antiparkinson medications on the modulation ol muscle activity (i.e., the ability to activate and inhibit each muscle throughout the course of a sequence). Results showed that the group with PD, before medication, moved more slowly and modulated muscle activity poorly compared to the control group. Antiparkinson medications improved movement speed as expected, although sequential movements remained slower than normal even after medication. Medication improved the ability to activate agonist muscle activity but did not improve the ability to inhibit antagonist activity. Instead, antagonist activity was also increased, resulting in minimal improvements in muscle modulation during sequential reaching movements.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 20`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements`
A11	`01`	`1`		`@1 KELLY (Valerie E.)`
A11	`02`	`1`		`@1 BASTIAN (Amy J.)`
A14	`01`			`@1 Department of Rehabilitation Medicine, University of Washington @2 Seattle, Washington @3 USA @Z 1 aut.`
A14	`02`			`@1 Kennedy Krieger Institute and Department of Neurology, Johns Hopkins University @2 Baltimore, Maryland @3 USA @Z 2 aut.`
A20				`@1 694-704`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000138604660060`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 25 ref.`
A47	`01`	`1`		`@0 05-0362495`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The execution of sequential arm movements is critical to activities of daily living such as eating and grooming. It is known that movement sequences are bradykinetic in people with Parkinson's disease (PD) and that antiparkinson medications improve the speed of movement sequences. However, it is unclear how muscle activity is modulated during sequential movements and what effect antiparkinson medications have on muscle modulation. We studied subjects with PD and age- and gender-matched control subjects making sequential reaching movements. Subjects with PD were tested before and after their morning dose of antiparkinson medications (levodopa and/or dopamine agonists). We examined the effect of antiparkinson medications on the modulation ol muscle activity (i.e., the ability to activate and inhibit each muscle throughout the course of a sequence). Results showed that the group with PD, before medication, moved more slowly and modulated muscle activity poorly compared to the control group. Antiparkinson medications improved movement speed as expected, although sequential movements remained slower than normal even after medication. Medication improved the ability to activate agonist muscle activity but did not improve the ability to inhibit antagonist activity. Instead, antagonist activity was also increased, resulting in minimal improvements in muscle modulation during sequential reaching movements.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B02B10`
C02	`03`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Chimiothérapie @5 09`
C03	`03`	`X`	`ENG`	`@0 Chemotherapy @5 09`
C03	`03`	`X`	`SPA`	`@0 Quimioterapia @5 09`
C03	`04`	`X`	`FRE`	`@0 Electromyographie @5 10`
C03	`04`	`X`	`ENG`	`@0 Electromyography @5 10`
C03	`04`	`X`	`SPA`	`@0 Electromiografía @5 10`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Electrophysiologie @5 41`
C07	`05`	`X`	`ENG`	`@0 Electrophysiology @5 41`
C07	`05`	`X`	`SPA`	`@0 Electrofisiología @5 41`
N21				`@1 255`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 05-0362495 INIST
ET :	Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements
AU :	KELLY (Valerie E.); BASTIAN (Amy J.)
AF :	Department of Rehabilitation Medicine, University of Washington/Seattle, Washington/Etats-Unis (1 aut.); Kennedy Krieger Institute and Department of Neurology, Johns Hopkins University/Baltimore, Maryland/Etats-Unis (2 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 6; Pp. 694-704; Bibl. 25 ref.
LA :	Anglais
EA :	The execution of sequential arm movements is critical to activities of daily living such as eating and grooming. It is known that movement sequences are bradykinetic in people with Parkinson's disease (PD) and that antiparkinson medications improve the speed of movement sequences. However, it is unclear how muscle activity is modulated during sequential movements and what effect antiparkinson medications have on muscle modulation. We studied subjects with PD and age- and gender-matched control subjects making sequential reaching movements. Subjects with PD were tested before and after their morning dose of antiparkinson medications (levodopa and/or dopamine agonists). We examined the effect of antiparkinson medications on the modulation ol muscle activity (i.e., the ability to activate and inhibit each muscle throughout the course of a sequence). Results showed that the group with PD, before medication, moved more slowly and modulated muscle activity poorly compared to the control group. Antiparkinson medications improved movement speed as expected, although sequential movements remained slower than normal even after medication. Medication improved the ability to activate agonist muscle activity but did not improve the ability to inhibit antagonist activity. Instead, antagonist activity was also increased, resulting in minimal improvements in muscle modulation during sequential reaching movements.
CC :	002B17; 002B02B10; 002B02B06
FD :	Système nerveux pathologie; Parkinson maladie; Chimiothérapie; Electromyographie
FG :	Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Electrophysiologie
ED :	Nervous system diseases; Parkinson disease; Chemotherapy; Electromyography
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Electrophysiology
SD :	Sistema nervioso patología; Parkinson enfermedad; Quimioterapia; Electromiografía
LO :	INIST-20953.354000138604660060
ID :	05-0362495

Links to Exploration step

Pascal:05-0362495

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements</title>
<author><name sortKey="Kelly, Valerie E" sort="Kelly, Valerie E" uniqKey="Kelly V" first="Valerie E." last="Kelly">Valerie E. Kelly</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Rehabilitation Medicine, University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bastian, Amy J" sort="Bastian, Amy J" uniqKey="Bastian A" first="Amy J." last="Bastian">Amy J. Bastian</name>
<affiliation><inist:fA14 i1="02"><s1>Kennedy Krieger Institute and Department of Neurology, Johns Hopkins University</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0362495</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0362495 INIST</idno>
<idno type="RBID">Pascal:05-0362495</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E66</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements</title>
<author><name sortKey="Kelly, Valerie E" sort="Kelly, Valerie E" uniqKey="Kelly V" first="Valerie E." last="Kelly">Valerie E. Kelly</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Rehabilitation Medicine, University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bastian, Amy J" sort="Bastian, Amy J" uniqKey="Bastian A" first="Amy J." last="Bastian">Amy J. Bastian</name>
<affiliation><inist:fA14 i1="02"><s1>Kennedy Krieger Institute and Department of Neurology, Johns Hopkins University</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term>
<term>Electromyography</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Chimiothérapie</term>
<term>Electromyographie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The execution of sequential arm movements is critical to activities of daily living such as eating and grooming. It is known that movement sequences are bradykinetic in people with Parkinson's disease (PD) and that antiparkinson medications improve the speed of movement sequences. However, it is unclear how muscle activity is modulated during sequential movements and what effect antiparkinson medications have on muscle modulation. We studied subjects with PD and age- and gender-matched control subjects making sequential reaching movements. Subjects with PD were tested before and after their morning dose of antiparkinson medications (levodopa and/or dopamine agonists). We examined the effect of antiparkinson medications on the modulation ol muscle activity (i.e., the ability to activate and inhibit each muscle throughout the course of a sequence). Results showed that the group with PD, before medication, moved more slowly and modulated muscle activity poorly compared to the control group. Antiparkinson medications improved movement speed as expected, although sequential movements remained slower than normal even after medication. Medication improved the ability to activate agonist muscle activity but did not improve the ability to inhibit antagonist activity. Instead, antagonist activity was also increased, resulting in minimal improvements in muscle modulation during sequential reaching movements.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>20</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KELLY (Valerie E.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BASTIAN (Amy J.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Rehabilitation Medicine, University of Washington</s1>
<s2>Seattle, Washington</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Kennedy Krieger Institute and Department of Neurology, Johns Hopkins University</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>694-704</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000138604660060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0362495</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The execution of sequential arm movements is critical to activities of daily living such as eating and grooming. It is known that movement sequences are bradykinetic in people with Parkinson's disease (PD) and that antiparkinson medications improve the speed of movement sequences. However, it is unclear how muscle activity is modulated during sequential movements and what effect antiparkinson medications have on muscle modulation. We studied subjects with PD and age- and gender-matched control subjects making sequential reaching movements. Subjects with PD were tested before and after their morning dose of antiparkinson medications (levodopa and/or dopamine agonists). We examined the effect of antiparkinson medications on the modulation ol muscle activity (i.e., the ability to activate and inhibit each muscle throughout the course of a sequence). Results showed that the group with PD, before medication, moved more slowly and modulated muscle activity poorly compared to the control group. Antiparkinson medications improved movement speed as expected, although sequential movements remained slower than normal even after medication. Medication improved the ability to activate agonist muscle activity but did not improve the ability to inhibit antagonist activity. Instead, antagonist activity was also increased, resulting in minimal improvements in muscle modulation during sequential reaching movements.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02B10</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Electromyographie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Electromyography</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Electromiografía</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Electrophysiologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Electrophysiology</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Electrofisiología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>255</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 05-0362495 INIST</NO>
<ET>Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements</ET>
<AU>KELLY (Valerie E.); BASTIAN (Amy J.)</AU>
<AF>Department of Rehabilitation Medicine, University of Washington/Seattle, Washington/Etats-Unis (1 aut.); Kennedy Krieger Institute and Department of Neurology, Johns Hopkins University/Baltimore, Maryland/Etats-Unis (2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2005; Vol. 20; No. 6; Pp. 694-704; Bibl. 25 ref.</SO>
<LA>Anglais</LA>
<EA>The execution of sequential arm movements is critical to activities of daily living such as eating and grooming. It is known that movement sequences are bradykinetic in people with Parkinson's disease (PD) and that antiparkinson medications improve the speed of movement sequences. However, it is unclear how muscle activity is modulated during sequential movements and what effect antiparkinson medications have on muscle modulation. We studied subjects with PD and age- and gender-matched control subjects making sequential reaching movements. Subjects with PD were tested before and after their morning dose of antiparkinson medications (levodopa and/or dopamine agonists). We examined the effect of antiparkinson medications on the modulation ol muscle activity (i.e., the ability to activate and inhibit each muscle throughout the course of a sequence). Results showed that the group with PD, before medication, moved more slowly and modulated muscle activity poorly compared to the control group. Antiparkinson medications improved movement speed as expected, although sequential movements remained slower than normal even after medication. Medication improved the ability to activate agonist muscle activity but did not improve the ability to inhibit antagonist activity. Instead, antagonist activity was also increased, resulting in minimal improvements in muscle modulation during sequential reaching movements.</EA>
<CC>002B17; 002B02B10; 002B02B06</CC>
<FD>Système nerveux pathologie; Parkinson maladie; Chimiothérapie; Electromyographie</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Electrophysiologie</FG>
<ED>Nervous system diseases; Parkinson disease; Chemotherapy; Electromyography</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Electrophysiology</EG>
<SD>Sistema nervioso patología; Parkinson enfermedad; Quimioterapia; Electromiografía</SD>
<LO>INIST-20953.354000138604660060</LO>
<ID>05-0362495</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E66 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001E66 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0362495
   |texte=   Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements

Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri